Published in Nat Med on August 06, 2013
The Complete Genome Sequences, Unique Mutational Spectra, and Developmental Potency of Adult Neurons Revealed by Cloning. Neuron (2016) 1.48
The Molecular Karyotype of 25 Clinical-Grade Human Embryonic Stem Cell Lines. Sci Rep (2015) 1.40
Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration. Sci Rep (2014) 1.20
Platform for induction and maintenance of transgene-free hiPSCs resembling ground state pluripotent stem cells. Stem Cell Reports (2014) 1.18
Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nat Rev Cardiol (2016) 1.13
Genomic instability in pluripotent stem cells: implications for clinical applications. J Biol Chem (2013) 1.13
Very small embryonic-like stem cells (VSELs) represent a real challenge in stem cell biology: recent pros and cons in the midst of a lively debate. Leukemia (2013) 1.10
Human pluripotent stem cell culture: considerations for maintenance, expansion, and therapeutics. Cell Stem Cell (2014) 1.10
Induced pluripotent stem cells for post-myocardial infarction repair: remarkable opportunities and challenges. Circ Res (2014) 1.09
Conditionally replicating adenovirus prevents pluripotent stem cell-derived teratoma by specifically eliminating undifferentiated cells. Mol Ther Methods Clin Dev (2015) 1.09
Elimination of tumorigenic human pluripotent stem cells by a recombinant lectin-toxin fusion protein. Stem Cell Reports (2015) 1.08
Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med (2016) 1.03
Path to the clinic: assessment of iPSC-based cell therapies in vivo in a nonhuman primate model. Cell Rep (2014) 1.01
The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies. J Biol Chem (2013) 1.00
Exosomes/microvesicles from induced pluripotent stem cells deliver cardioprotective miRNAs and prevent cardiomyocyte apoptosis in the ischemic myocardium. Int J Cardiol (2015) 0.98
Hurdles to clinical translation of human induced pluripotent stem cells. J Clin Invest (2015) 0.98
Small Molecules Efficiently Reprogram Human Astroglial Cells into Functional Neurons. Cell Stem Cell (2015) 0.98
Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle (2014) 0.97
Stem cell-based therapies for cancer treatment: separating hope from hype. Nat Rev Cancer (2014) 0.96
Finding Expandable Induced Cardiovascular Progenitor Cells. Circ Res (2016) 0.96
Costimulation-adhesion blockade is superior to cyclosporine A and prednisone immunosuppressive therapy for preventing rejection of differentiated human embryonic stem cells following transplantation. Stem Cells (2013) 0.95
Moving stem cells to the clinic: potential and limitations for brain repair. Neuron (2015) 0.94
Are hematopoietic stem cells involved in hepatocarcinogenesis? Hepatobiliary Surg Nutr (2014) 0.94
Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol (2015) 0.93
Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies. Stem Cells Transl Med (2015) 0.92
An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells. Mol Ther (2015) 0.90
Tracking gene and cell fate for therapeutic gain. Nat Mater (2014) 0.88
Potential Strategies to Address the Major Clinical Barriers Facing Stem Cell Regenerative Therapy for Cardiovascular Disease: A Review. JAMA Cardiol (2016) 0.86
Expression of the erythropoietin receptor by germline-derived cells - further support for a potential developmental link between the germline and hematopoiesis. J Ovarian Res (2014) 0.86
The myocardial regenerative potential of three-dimensional engineered cardiac tissues composed of multiple human iPS cell-derived cardiovascular cell lineages. Sci Rep (2016) 0.85
miR-367 promotes proliferation and stem-like traits in medulloblastoma cells. Cancer Sci (2015) 0.85
Teratoma formation: a tool for monitoring pluripotency in stem cell research. Curr Protoc Stem Cell Biol (2015) 0.85
Drug delivery, cell-based therapies, and tissue engineering approaches for spinal cord injury. J Control Release (2015) 0.85
Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand? EMBO Mol Med (2015) 0.85
Immunogenicity and tumorigenicity of pluripotent stem cells and their derivatives: genetic and epigenetic perspectives. Curr Stem Cell Res Ther (2014) 0.84
The role of growth factors in stem cell-directed chondrogenesis: a real hope for damaged cartilage regeneration. Int Orthop (2014) 0.83
Human Induced Pluripotent Stem Cells Are Targets for Allogeneic and Autologous Natural Killer (NK) Cells and Killing Is Partly Mediated by the Activating NK Receptor DNAM-1. PLoS One (2015) 0.82
A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy. Stem Cell Reports (2015) 0.82
Direct optical activation of skeletal muscle fibres efficiently controls muscle contraction and attenuates denervation atrophy. Nat Commun (2015) 0.82
Metabolic control of cancer cell stemness: Lessons from iPS cells. Cell Cycle (2015) 0.81
Repair of Ischemic Injury by Pluripotent Stem Cell Based Cell Therapy without Teratoma through Selective Photosensitivity. Stem Cell Reports (2015) 0.81
Comparison of Magnetic Resonance Imaging and Serum Biomarkers for Detection of Human Pluripotent Stem Cell-Derived Teratomas. Stem Cell Reports (2016) 0.81
Directed cardiomyogenesis of autologous human induced pluripotent stem cells recruited to infarcted myocardium with bioengineered antibodies. Mol Cell Ther (2014) 0.81
The Role of Nonhuman Primate Animal Models in the Clinical Development of Pluripotent Stem Cell Therapies. Mol Ther (2016) 0.81
Cell-based therapy technology classifications and translational challenges. Philos Trans R Soc Lond B Biol Sci (2015) 0.80
Differentiation of Cardiomyocytes from Human Pluripotent Stem Cells Using Monolayer Culture. Biomark Insights (2015) 0.80
Directed differentiation of induced pluripotent stem cells into chondrogenic lineages for articular cartilage treatment. J Tissue Eng (2014) 0.80
Strategies and Challenges to Myocardial Replacement Therapy. Stem Cells Transl Med (2016) 0.80
Alternative cultures for human pluripotent stem cell production, maintenance, and genetic analysis. J Vis Exp (2014) 0.80
Bioimaging: An Useful Tool to Monitor Differentiation of Human Embryonic Stem Cells into Chondrocytes. Ann Biomed Eng (2015) 0.79
Developmental insights from early mammalian embryos and core signaling pathways that influence human pluripotent cell growth and differentiation. Stem Cell Res (2014) 0.79
Characterization of Neurogenic Potential of Dental Pulp Stem Cells Cultured in Xeno/Serum-Free Condition: In Vitro and In Vivo Assessment. Stem Cells Int (2016) 0.78
Development of a Safeguard System Using an Episomal Mammalian Artificial Chromosome for Gene and Cell Therapy. Mol Ther Nucleic Acids (2015) 0.78
Embryonic Stem Cells Promoting Macrophage Survival and Function are Crucial for Teratoma Development. Front Immunol (2014) 0.78
Ethics of iPSC-based clinical research for age-related macular degeneration: patient-centered risk-benefit analysis. Stem Cell Rev (2014) 0.78
Pluripotent muse cells derived from human adipose tissue: a new perspective on regenerative medicine and cell therapy. Clin Transl Med (2014) 0.78
Escape Mutations, Ganciclovir Resistance, and Teratoma Formation in Human iPSCs Expressing an HSVtk Suicide Gene. Mol Ther Nucleic Acids (2016) 0.78
Inhibition of an NAD⁺ salvage pathway provides efficient and selective toxicity to human pluripotent stem cells. Stem Cells Transl Med (2015) 0.78
Mitochondria in human pluripotent stem cell apoptosis. Semin Cell Dev Biol (2016) 0.77
A mystery unraveled: nontumorigenic pluripotent stem cells in human adult tissues. Expert Opin Biol Ther (2014) 0.77
Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov (2016) 0.77
Tumourigenicity and Immunogenicity of Induced Neural Stem Cell Grafts Versus Induced Pluripotent Stem Cell Grafts in Syngeneic Mouse Brain. Sci Rep (2016) 0.77
A cell engineering strategy to enhance the safety of stem cell therapies. Cell Rep (2014) 0.77
Cancer-like epigenetic derangements of human pluripotent stem cells and their impact on applications in regeneration and repair. Curr Opin Genet Dev (2014) 0.77
Elimination of proliferating cells from CNS grafts using a Ki67 promoter-driven thymidine kinase. Mol Ther Methods Clin Dev (2016) 0.77
Stem cell therapy: a look at current research, regulations, and remaining hurdles. P T (2014) 0.76
Aptamer technology for tracking cells' status & function. Mol Cell Ther (2014) 0.76
Tumor prevention facilitates delayed transplant of stem cell-derived motoneurons. Ann Clin Transl Neurol (2016) 0.76
Tumor-free iPS stem cells for heart cells. Cell Cycle (2014) 0.76
Techniques of Human Embryonic Stem Cell and Induced Pluripotent Stem Cell Derivation. Arch Immunol Ther Exp (Warsz) (2016) 0.75
Employment of the Triple Helix concept for development of regenerative medicine applications based on human pluripotent stem cells. Clin Transl Med (2014) 0.75
Insulin-secreting β cells require a post-genomic concept. World J Diabetes (2016) 0.75
Neural Stem Cell Tumorigenicity and Biodistribution Assessment for Phase I Clinical Trial in Parkinson's Disease. Sci Rep (2016) 0.75
The Tumorigenicity of Multipotent Adult Germline Stem Cells Transplanted into the Heart Is Affected by Natural Killer Cells and by Cyclosporine A Independent of Its Immunosuppressive Effects. Front Immunol (2017) 0.75
Rapid and efficient generation of neural progenitors from adult bone marrow stromal cells by hypoxic preconditioning. Stem Cell Res Ther (2016) 0.75
Bioengineering of injectable encapsulated aggregates of pluripotent stem cells for therapy of myocardial infarction. Nat Commun (2016) 0.75
Surgical Neurostimulation for Spinal Cord Injury. Brain Sci (2017) 0.75
Preclinical Liver Bud Engineering towards Clinical Target for Liver Diseases. J Clin Exp Hepatol (2014) 0.75
Viral Vector-Based Innovative Approaches to Directly Abolishing Tumorigenic Pluripotent Stem Cells for Safer Regenerative Medicine. Mol Ther Methods Clin Dev (2017) 0.75
Immortalization of Human Fetal Hepatocyte by Ectopic Expression of Human Telomerase Reverse Transcriptase, Human Papilloma Virus (E7) and Simian Virus 40 Large T (SV40 T) Antigen Towards Bioartificial Liver Support. J Clin Exp Hepatol (2014) 0.75
Gene Expression Profiling in the Injured Spinal Cord of Trachemys scripta elegans: An Amniote with Self-Repair Capabilities. Front Mol Neurosci (2017) 0.75
Current Strategies and Challenges for Purification of Cardiomyocytes Derived from Human Pluripotent Stem Cells. Theranostics (2017) 0.75
Chemicals as the Sole Transformers of Cell Fate. Int J Stem Cells (2016) 0.75
Current Biosafety Considerations in Stem Cell Therapy. Cell J (2016) 0.75
Co-Registration of Bioluminescence Tomography, Computed Tomography, and Magnetic Resonance Imaging for Multimodal In Vivo Stem Cell Tracking. Tomography (2016) 0.75
Glypican 4 down-regulation in pluripotent stem cells as a potential strategy to improve differentiation and to impair tumorigenicity of cell transplants. Neural Regen Res (2015) 0.75
Generating size-controlled embryoid bodies using laser direct-write. Biofabrication (2014) 0.75
Concise review: animal substance-free human embryonic stem cells aiming at clinical applications. Stem Cells Transl Med (2014) 0.75
Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells. Oncogene (2017) 0.75
Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers. Pflugers Arch (2016) 0.75
Quercetin induced ROS production triggers mitochondrial cell death of human embryonic stem cells. Oncotarget (2016) 0.75
The Promise and Challenge of Induced Pluripotent Stem Cells for Cardiovascular Applications. JACC Basic Transl Sci (2016) 0.75
Topical tissue nano-transfection mediates non-viral stroma reprogramming and rescue. Nat Nanotechnol (2017) 0.75
Generation of germline-competent induced pluripotent stem cells. Nature (2007) 32.77
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67
Human induced pluripotent stem cells free of vector and transgene sequences. Science (2009) 17.16
Dissecting direct reprogramming through integrative genomic analysis. Nature (2008) 16.47
Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell (2010) 14.18
Induced pluripotent stem cells generated without viral integration. Science (2008) 13.38
Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell (2009) 13.02
piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature (2009) 11.27
Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell (2005) 9.84
Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet (2004) 9.35
Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat Biotechnol (2003) 9.15
Induction of tumors in mice by genomic hypomethylation. Science (2003) 8.86
c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell (2007) 8.46
Transcriptional amplification in tumor cells with elevated c-Myc. Cell (2012) 8.24
Copy number variation and selection during reprogramming to pluripotency. Nature (2011) 8.24
Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature (2011) 7.90
Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet (2012) 7.70
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Reflecting on 25 years with MYC. Nat Rev Cancer (2008) 7.44
Immunogenicity of induced pluripotent stem cells. Nature (2011) 7.31
Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med (2006) 7.21
Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell (2010) 7.16
Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell (2011) 6.82
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell (2010) 6.00
Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med (2009) 5.50
Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell (2002) 4.56
The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol (2005) 4.29
Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature (2013) 4.19
Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol (2011) 3.97
Chromosome instability is common in human cleavage-stage embryos. Nat Med (2009) 3.85
The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer (2011) 3.42
High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat Biotechnol (2010) 3.21
Combined management of malignant teratoma of the testis. Lancet (1979) 3.12
An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol (2011) 3.05
Activation of innate immunity is required for efficient nuclear reprogramming. Cell (2012) 2.99
Lab-specific gene expression signatures in pluripotent stem cells. Cell Stem Cell (2010) 2.95
Human embryonic stem cells reveal recurrent genomic instability at 20q11.21. Nat Biotechnol (2008) 2.84
SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat Biotechnol (2011) 2.84
Geron trial resumes, but standards for stem cell trials remain elusive. Nat Biotechnol (2010) 2.81
Recurrent chromosomal abnormalities in human embryonic stem cells. Nat Biotechnol (2008) 2.79
Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. J Clin Invest (2011) 2.69
Characterization of human embryonic stem cells with features of neoplastic progression. Nat Biotechnol (2009) 2.66
Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A (2002) 2.53
Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci U S A (2011) 2.51
Transgenic mice with defined combinations of drug-inducible reprogramming factors. Nat Biotechnol (2009) 2.46
Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell (2013) 2.45
Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci U S A (2010) 2.44
Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell (2011) 2.35
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell (2012) 2.26
Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci U S A (2008) 2.25
Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell (2013) 2.02
Selection against undifferentiated human embryonic stem cells by a cytotoxic antibody recognizing podocalyxin-like protein-1. Stem Cells (2008) 1.83
CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells. Nat Biotechnol (2006) 1.58
Prolonged maturation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson's disease. Stem Cells (2012) 1.41
Stem cells cruise to clinic. Nature (2013) 1.24
Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. Cancer Res (2010) 1.24
Human embryonic stem cells fail to activate CHK1 and commit to apoptosis in response to DNA replication stress. Stem Cells (2012) 1.02
Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. Cancer Lett (2012) 1.01
WNT signaling determines tumorigenicity and function of ESC-derived retinal progenitors. J Clin Invest (2013) 1.00
Deficient DNA damage response and cell cycle checkpoints lead to accumulation of point mutations in human embryonic stem cells. Stem Cells (2012) 0.98
Using small molecules to improve generation of induced pluripotent stem cells from somatic cells. Methods Mol Biol (2010) 0.97
Strange lesions after stem-cell therapy. Nature (2010) 0.82
Discriminating cellular heterogeneity using microwell-based RNA cytometry. Nat Commun (2014) 0.92